CL2023002321A1 - Abridor de canales de potasio activado por voltaje para uso en el tratamiento de la anhedonia. - Google Patents
Abridor de canales de potasio activado por voltaje para uso en el tratamiento de la anhedonia.Info
- Publication number
- CL2023002321A1 CL2023002321A1 CL2023002321A CL2023002321A CL2023002321A1 CL 2023002321 A1 CL2023002321 A1 CL 2023002321A1 CL 2023002321 A CL2023002321 A CL 2023002321A CL 2023002321 A CL2023002321 A CL 2023002321A CL 2023002321 A1 CL2023002321 A1 CL 2023002321A1
- Authority
- CL
- Chile
- Prior art keywords
- anhedonia
- treatment
- voltage
- potassium channel
- channel opener
- Prior art date
Links
- 208000007415 Anhedonia Diseases 0.000 title abstract 3
- 150000003109 potassium Chemical class 0.000 title 1
- 239000004036 potassium channel stimulating agent Substances 0.000 title 1
- 229940126062 Compound A Drugs 0.000 abstract 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- FJNPZKZPWVVSON-UHFFFAOYSA-N n-[4-(6-fluoro-3,4-dihydro-1h-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide Chemical compound CC1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CC3=CC=C(F)C=C3CC2)=C1 FJNPZKZPWVVSON-UHFFFAOYSA-N 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Shovels (AREA)
- Ignition Installations For Internal Combustion Engines (AREA)
- Electrotherapy Devices (AREA)
Abstract
La presente divulgación está dirigida, entre otras cosas, a métodos y usos para tratar la anhedonia en un sujeto, como un ser humano, en los que los métodos comprenden administrar una cantidad terapéuticamente eficaz de N-[4-(6- fluoro-3,4-dihidro-1H-isoquinolin-2-il)-2,6-dimetilfenil]-3,3-dimetilbutanamida (Compuesto A) al sujeto que lo necesita, y los usos comprenden el Compuesto A para usar en el tratamiento de la anhedonia en un sujeto, tal como humano La presente divulgación se dirige además a varios métodos mejorados de terapia y administración del Compuesto A.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163147742P | 2021-02-09 | 2021-02-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023002321A1 true CL2023002321A1 (es) | 2024-03-08 |
Family
ID=80445983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023002321A CL2023002321A1 (es) | 2021-02-09 | 2023-08-07 | Abridor de canales de potasio activado por voltaje para uso en el tratamiento de la anhedonia. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11957675B2 (es) |
| EP (1) | EP4291189A1 (es) |
| JP (1) | JP2024508660A (es) |
| KR (1) | KR20240004241A (es) |
| CN (1) | CN116847843A (es) |
| AU (1) | AU2022220675A1 (es) |
| CA (1) | CA3207191A1 (es) |
| CL (1) | CL2023002321A1 (es) |
| IL (1) | IL304920A (es) |
| MA (1) | MA61732A1 (es) |
| MX (1) | MX2023009314A (es) |
| TW (1) | TW202245744A (es) |
| WO (1) | WO2022173855A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240004238A (ko) * | 2021-02-09 | 2024-01-11 | 제논 파마슈티칼스 인크. | 발작 장애를 치료하기 위한 합동 요법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009535370A (ja) | 2006-05-02 | 2009-10-01 | クリス ルントフェルト | ジストニアおよびジストニア様症状の予防および治療におけるカリウムチャンネル活性剤 |
| US8993593B2 (en) | 2006-08-23 | 2015-03-31 | Valeant Pharmaceuticals International | N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators |
| NZ575652A (en) | 2006-08-23 | 2011-08-26 | Valeant Pharmaceuticals Int | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators |
| US20100256145A1 (en) * | 2007-08-01 | 2010-10-07 | H. Lundbeck A/S | Use of kcnq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted |
| MD3790548T2 (ro) | 2018-05-11 | 2024-02-29 | Xenon Pharmaceuticals Inc | Metode de îmbunătățire a biodisponibilității și expunerii activatorului de canale de potasiu voltaj-dependente |
| TW202128627A (zh) | 2019-10-10 | 2021-08-01 | 加拿大商再諾製藥公司 | 選擇性鉀通道調節劑之固態晶型 |
| WO2021092439A1 (en) | 2019-11-08 | 2021-05-14 | Xenon Pharmaceuticals Inc. | Methods of treating depressive disorders |
| CA3159876A1 (en) | 2019-12-06 | 2021-06-10 | James MURROUGH | Method of treatment with kcnq channel openers |
-
2022
- 2022-02-09 CN CN202280014279.1A patent/CN116847843A/zh active Pending
- 2022-02-09 MX MX2023009314A patent/MX2023009314A/es unknown
- 2022-02-09 EP EP22705687.6A patent/EP4291189A1/en active Pending
- 2022-02-09 TW TW111104798A patent/TW202245744A/zh unknown
- 2022-02-09 CA CA3207191A patent/CA3207191A1/en active Pending
- 2022-02-09 KR KR1020237030629A patent/KR20240004241A/ko unknown
- 2022-02-09 US US17/668,340 patent/US11957675B2/en active Active
- 2022-02-09 IL IL304920A patent/IL304920A/en unknown
- 2022-02-09 MA MA61732A patent/MA61732A1/fr unknown
- 2022-02-09 JP JP2023547490A patent/JP2024508660A/ja active Pending
- 2022-02-09 WO PCT/US2022/015854 patent/WO2022173855A1/en active Application Filing
- 2022-02-09 AU AU2022220675A patent/AU2022220675A1/en active Pending
-
2023
- 2023-08-07 CL CL2023002321A patent/CL2023002321A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023009314A (es) | 2023-08-16 |
| CN116847843A (zh) | 2023-10-03 |
| AU2022220675A1 (en) | 2023-09-21 |
| MA61732A1 (fr) | 2024-01-31 |
| US20220265634A1 (en) | 2022-08-25 |
| EP4291189A1 (en) | 2023-12-20 |
| JP2024508660A (ja) | 2024-02-28 |
| IL304920A (en) | 2023-10-01 |
| CA3207191A1 (en) | 2022-08-18 |
| KR20240004241A (ko) | 2024-01-11 |
| US11957675B2 (en) | 2024-04-16 |
| TW202245744A (zh) | 2022-12-01 |
| WO2022173855A1 (en) | 2022-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023002321A1 (es) | Abridor de canales de potasio activado por voltaje para uso en el tratamiento de la anhedonia. | |
| CL2021002965A1 (es) | Compuestos antivirales que contienen nitrilo. | |
| CO2020015476A2 (es) | Métodos para potenciar la biodisponibilidad y la exposición de un abridor de canales de potasio dependientes de voltaje | |
| CO2023000703A2 (es) | Métodos de tratamiento del cáncer mediante derivados heteroaril-bifenil-amida | |
| CL2022001102A1 (es) | Métodos para el tratamiento de trastornos depresivos. | |
| CL2022002566A1 (es) | Combinaciones de brimonidina de dosis baja y usos de las mismas. (solicitud divisional de 201903572) | |
| CL2021003032A1 (es) | Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton | |
| EA201071043A1 (ru) | Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 и cx3cr1 | |
| CL2021003034A1 (es) | Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton | |
| ECSP23048974A (es) | Compuesto de heteroarilcarboxamida | |
| CO2024001102A2 (es) | Compuestos de pirazolopiridinona | |
| CL2022001477A1 (es) | Uso de un abridor de canal de potasio kv7 para tratar el dolor | |
| CO2023014650A2 (es) | Dosificación y administración de l-asparaginasa recombinante | |
| CO2023011948A2 (es) | Terapia conjunta para el tratamiento de trastornos convulsivos | |
| CO2021011328A2 (es) | Derivados de 2h-indazol como agentes terapéuticos para cánceres cerebrales y metástasis cerebrales | |
| AR121518A1 (es) | Métodos para usar rebastinib en el tratamiento de trastornos | |
| BR112023022647A2 (pt) | Derivado de 7-nitro-8-hidroxiquinolina, método de preparação do mesmo e uso médico do mesmo | |
| AR122344A1 (es) | Uso de reboxetina para tratar desórdenes del sistema nervioso | |
| EA202091968A1 (ru) | Составы эпинефрина в виде спрея | |
| CL2022003031A1 (es) | Composicion que comprende albumina para su utilizacion en el tratamiento de la esclerosis lateral amiotrofica (ela) mediante recambio plasmatico | |
| AR125331A1 (es) | Combinación que comprende ribociclib y amcenestrant | |
| PE20230181A1 (es) | Uso de reboxetina para tratar los trastornos del sistema nervioso | |
| CL2023002497A1 (es) | Uso de inhibidores de bet como tratamiento para la mielofibrosis | |
| CL2022001476A1 (es) | Uso de reboxetina para tratar los trastornos del sistema nervioso | |
| AR114854A1 (es) | Métodos para el tratamiento del cáncer |